QZQianjun Zhuang

Qianjun Zhuang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qianjun Zhuang has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association Between Psychological Burden and Unexplained High Upper Esophageal Sphincter Basal Pressure

    by Dianxuan Jiang, Qianjun Zhuang, Songfeng Chen, Xingyu Jia, Jing Chen, Niandi Tan, Mengyu Zhang, Yinglian Xiao

    Proximal esophageal dysmotility and high psychological burden are common in individuals with esophageal or laryngopharyngeal reflux symptoms. However, the clinical significance of abnormal proximal motility remains unclear. Given that proximal esophagus consists of skeletal muscle, proximal esophageal motility may be influenced by psychological burden. This study aims to explore the relationship between psychological burden and proximal esophageal motility. Patients with esophageal or laryngopharyngeal reflux symptoms were retrospectively included. Esophageal hypervigilance and anxiety scale (EHAS) was used to evaluate the psychological burden in patients. Demographics, endoscopic findings, proximal and distal esophageal manometric parameters, and reflux burden were compared between patients with and without esophageal hypervigilance and anxiety. Multivariate logistic regression analysis was conducted to determine the relationship between psychological burden and proximal esophageal motility. A total of 341 subjects were enrolled. A greater proportion of patients with high EHAS had elevated upper esophageal sphincter (UES) basal pressure than those with normal EHAS (21.5% vs 11.8%, P = 0.024), while no significant difference was found in other proximal manometric parameters between the 2 groups. On multivariate analysis, high EHAS was independently associated with elevated UES basal pressure (OR, 2.19, P = 0.034). Elevated UES basal pressure is more frequently seen in symptomatic patients with high esophageal hypervigilance and anxiety. When encountering patients with unexplained high UES basal pressure, psychological burden may play a potential role in these cases.


  • Differential Neurogenesis Status Among Achalasia Subtypes

    by Qianjun Zhuang, Niandi Tan, Xun Hou, Songfeng Chen, Xingyu Jia, Mengyu Zhang, Fangfei Chen, Zhanye Zhang, Xiangbin Xing, Yinglian Xiao

    Backgrounds and Aims: Achalasia is an acquired esophageal neurodegenerative disorder, characterized by selective loss of inhibitory neurons in the myenteric plexus of the lower esophageal sphincter (LES). The Enteric neural precursor cell (ENPC) is essential in maintaining neurogenesis, but its role in achalasia pathogenesis is unknown. This study aimed to explore the neurogenesis status in the LES among achalasia patients.Methods: LES specimens from 59 patients with achalasia who underwent peroral endoscopic myotomy (POEM) and from 19 controls with esophageal cancer were examined. Double‐labeled immunofluorescence staining was performed to evaluate Nestin‐expressing ENPC and axonal innervation in the LES. Immunofluorescence values were compared between groups and correlated with clinical variables, including demographics, disease duration, Eckardt score, manometric parameters, and treatment outcome.Key Results: A significant reduction of Nestin‐positive cells, PGP9.5‐ and nNOS‐labeled axon innervation was observed in achalasia. The number of Nestin‐positive cells significantly correlated with axon innervation, confirming their roles in neurogenesis. The number of Nestin‐positive cells, immature total axons (Nestin+PGP9.5+) and immature nitrergic axons (Nestin+nNOS+) were different among achalasia subtypes. Type 2 achalasia exhibited a more severe loss of both ENPC and axon innervation, while type 1 achalasia was characterized by retained ENPC and immature nitrergic axons, but with severe depletion of mature axons (Nestin−nNOS+).Conclusions: Neurogenesis is generally impaired in achalasia; however, the status of neurogenesis varies across different manometric subtypes, suggesting that the pathophysiology of each subtype may be distinct.


  • POETry Without Motion: When Per-oral Endoscopic Myotomy (POEM) Fails

    by Mengyu Zhang, Qianjun Zhuang, Niandi Tan, Yinglian Xiao, George Triadafilopoulos

  • Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis

    by Qianjun Zhuang, Songfeng Chen, Xuyu Zhou, Xingyu Jia, Mengyu Zhang, Niandi Tan, Fangfei Chen, Zhanye Zhang, Junnan Hu, Yinglian Xiao

    INTRODUCTION: Los Angeles grade C/D esophagitis is a severe manifestation of gastroesophageal reflux disease that require active treatment and close follow-up. Potassium competitive acid blockers (P-CAB) are promising alternatives to proton pump inhibitors (PPI). We aimed to compare the efficacy and safety of P-CAB and PPI in healing grade C/D esophagitis to aid clinical decision-making. METHODS: A systematic literature search was performed using PubMed, MEDLINE, and Cochrane Central Register of Controlled Trials. Randomized controlled trials were eligible for inclusion if efficacy of P-CAB and PPI in healing grade C/D esophagitis was reported. Pooled risk ratios and risk difference with 95% credible intervals were used to summarize estimated effect of each comparison. The benefit of treatments was ranked using the surface under the cumulative probability ranking score. RESULTS: Of 5,876 articles identified in the database, 24 studies were eligible. Studies included incorporated 3 P-CAB (vonoprazan, tegoprazan, and keverprazan) and 6 PPI (lansoprazole, esomeprazole, omeprazole, rabeprazole extended-release (ER), pantoprazole, and dexlansoprazole). Based on the failure to achieve mucosal healing, 20 mg of vonoprazan q.d. ranked the first among PPI in initial and maintained healing of grade C/D esophagitis (surface under the cumulative probability ranking score = 0.89 and 0.87, respectively). Vonoprazan had similar risk of incurring adverse events, severe adverse events, and withdrawal to drug when compared with PPI. For those who attempted lower maintenance treatment dose, 10 mg of vonoprazan q.d. was a reasonable choice, considering its moderate efficacy and safety. DISCUSSION: Vonoprazan has considerable efficacy in initial and maintained healing of grade C/D esophagitis compared with PPI, with moderate short-term and long-term safety.


  • Two‐year outcomes of anti‐reflux mucosectomy in treating gastroesophageal reflux disease: A Chinese prospective cohort study

    by Jun Nan Hu, Song Feng Chen, Xing Yu Jia, Yu Luo, Xiang Bin Xing, Nian Di Tan, Meng Yu Zhang, Qian Jun Zhuang, Jin Hui Wang, Ying Lian Xiao

    Objectives: Anti‐reflux mucosectomy (ARMS) is an emerging and promising endoscopic treatment for gastroesophageal reflux disease (GERD). In the current study we aimed to evaluate the safety and efficacy of ARMS in treating Chinese GERD patients.Methods: This was a single‐center prospective cohort study. ARMS was performed in GERD patients by an experienced endoscopist. The patients were required to undergo symptom assessment as well as endoscopic examination, high‐resolution manometry (HRM), and impedance‐pH monitoring before and after ARMS.Results: Twelve patients were enrolled. Follow‐up was completed by all patients at 3 and 6 months, 11 patients at 1 year, and 8 patients at 2 years after ARMS, respectively. Symptom improvement was achieved in 66.7%, 75.0%, 72.7%, and 50.0% of the patients at 3 months, 6 months, 1 year, and 2 years after ARMS, respectively. Postoperative dysphagia was reported by 25.0%, 25.0%, 27.3%, and 25.0% of patients at 3 months, 6 months, 1 year, and 2 years after surgery, none of whom required additional invasive treatment. All patients with preoperative esophagitis healed after ARMS. For impedance‐pH monitoring parameters, number of acidic reflux episodes and the proportion of patients with acid exposure time (AET) >4.0% decreased significantly after ARMS.Conclusions: ARMS was safe and effective in Chinese GERD patients. The efficacy of ARMS was not short‐term and remained evident throughout the 2‐year follow‐up. Further multicenter studies with larger sample sizes are needed to verify our findings.


  • Open Access

    Development and Validation of Serum Markers as Noninvasive Diagnostic Methods for Achalasia

    by Xingyu Jia, Songfeng Chen, Xun Hou, Qianjun Zhuang, Niandi Tan, Mengyu Zhang, Jinhui Wang, Xiangbin Xing, Yinglian Xiao

    INTRODUCTION: Currently, the diagnosis of achalasia mainly relies on invasive or radioactive examinations. This study aimed to develop a noninvasive diagnostic method for achalasia based on specific serum markers. METHODS: Serum levels of profilin-1, galectin-10, immunoglobulin heavy variable 3–9, vasodilator-stimulated phosphoprotein, and transgelin-2 were measured in patients with achalasia and controls by enzyme-linked immunosorbent assay. The diagnostic values and thresholds were determined by the receiver operating characteristic curve analysis. Then, patients with dysphagia were prospectively enrolled to validate the ability of these molecules for achalasia diagnosing. RESULTS: A total of 142 patients with achalasia and 50 nonachalasia controls (healthy volunteers and patients with reflux esophagitis) were retrospectively included. The serum levels of profilin-1, galectin-10, and transgelin-2 in patients with achalasia were significantly higher than those in healthy volunteers and patients with reflux esophagitis (P all < 0.001). Profilin-1, galectin-10, and transgelin-2 were of good performance in diagnosing achalasia, with optimal thresholds of 2,171.2, 33.9, and 1,630.6 pg/mL, respectively. Second, 40 patients with dysphagia were prospectively enrolled to the validation of achalasia. For profilin-1, the positive predictive value, negative predictive value, sensitivity, and specificity were 100.0%, 64.5%, 45.0%, and 100.0%, respectively. The figures for transgelin-2 were 65.5%, 90.9%, 95.0%, and 50.0%. When both increased, the positive predictive value reached to 100.0%. When both indexes were normal, the negative predictive value was 100.0%. DISCUSSION: Profilin-1 and transgelin-2 were promising biomarkers for achalasia diagnosis and performed better in combination. Further multicenter studies are necessary to verify their application as preliminary screening tools for achalasia.


  • Patients at risk for further examination with conventional gastroscopy after undergoing magnetically controlled capsule endoscopy

    by Ting Ting Wu, Meng Yu Zhang, Nian Di Tan, Song Feng Chen, Qian Jun Zhuang, Yu Luo, Ying Lian Xiao

    Objective: In this study we aimed to compare the need for further examination with conventional gastroscopy within 1 year after magnetically assisted capsule endoscopy (MCCE) examination between patients with gastrointestinal (GI) symptoms and asymptomatic individuals.Methods: After propensity score matching analysis, 372 patients with GI symptoms and 372 asymptomatic individuals who had undergone MCCE at the First Affiliated Hospital of Sun Yat‐sen University from January 1, 2019 to December 30, 2020 were retrospectively enrolled. Demographic and clinical characteristics of the participants and their MCCE and gastroscopic findings (performed within 1 year after MCCE) were analyzed.Results: Fifty‐one (6.85%) patients underwent further examination with conventional gastroscopy within 1 year after MCCE. Those with GI symptoms were more likely to undergo conventional gastroscopy than those without (9.95% vs 3.76%, P < 0.001). Polyps were the most common finding of MCCE. The rate of conventional gastroscopy in patients with focal lesions was significantly higher than that in those without focal lesions (P < 0.05). However, such rate did not differ in the different age groups (P = 0.106).Conclusions: MCCE is an optimal alternative for gastric examination, especially for large‐scale screening of asymptomatic individuals. Patients with GI symptoms or focal lesions detected by MCCE are more likely to seek further examination with conventional gastroscopy for biopsy or endoscopic treatment than those without.


  • Open Access

    Achalasia: The Current Clinical Dilemma and Possible Pathogenesis

    by Xingyu Jia, Songfeng Chen, Qianjun Zhuang, Niandi Tan, Mengyu Zhang, Yi Cui, Jinhui Wang, Xiangbin Xing, Yinglian Xiao

    Xingyu Jia, Songfeng Chen, Qianjun Zhuang, Niandi Tan, Mengyu Zhang, Yi Cui, Jinhui Wang, Xiangbin Xing, and Yinglian Xiao*. J Neurogastroenterol Motil 2023;29:145-55. https://doi.org/10.5056/jnm22176


  • Patient‐ and physician‐reported satisfaction with gastroesophageal reflux disease ( GERD ) treatment in Chinese clinical practice

    by Ying Lian Xiao, Meng Yu Zhang, Nian Di Tan, Song Feng Chen, Qian Jun Zhuang, Min Hu Chen

    Objective The aim of this study was to assess the level of satisfaction with currently prescribed medications for gastroesophageal reflux disease (GERD) in patients and physicians in China. Methods Physicians across China were invited to complete physician surveys concerning factors affecting the prescription of medication for GERD and their satisfaction through an online questionnaire. The enrolled physicians invited the first five GERD patients who visited them on the same day to complete online patient surveys concerning the satisfaction with medications for GERD and its influencing factors. Results In total, 334 physician surveys (response rate 36.82%) and 1409 patient surveys (86.07%) were analyzed. Over half (62.57%) the physicians recommended taking a proton pump inhibitor (PPI) twice daily and the majority (88.02%) recommended taking a PPI for 1 week to 3 months. Factors affecting the prescription were how much it could improve quality of life (84.73%), followed by safety, medication compliance, and efficacy. Approximately 30% of patients reported taking a PPI twice daily and 47.20% reported taking a PPI for 1 week to 3 months. Factor affecting patients' adherence to medications was safety (64.30%), followed by medical insurance, efficacy and convenience. Approximately one-third of physicians and patients did not report "satisfied" or "very satisfied" with medications for GERD, including 10.51% of patients and 12.87% of physicians reporting "dissatisfied" or "very dissatisfied." Conclusion One-third of GERD patients and physicians were not satisfied or very satisfied with medications for GERD. Novel medications may help optimize the management of GERD.


  • Magnetic sphincter augmentation in treating refractory gastroesophageal reflux disease: A systematic review and meta‐analysis

    by Qian Jun Zhuang, Nian Di Tan, Song Feng Chen, Meng Yu Zhang, Ying Lian Xiao

    Objective: In this systematic review and meta‐analysis we aimed to determine the efficacy and safety of magnetic sphincter augmentation (MSA) in the management of refractory gastroesophageal reflux disease (rGERD).Methods: Literature search was conducted in PubMed, the Cochrane Library, EMBASE, Web of Science, OpenGrey and ClincalTrials.gov for single‐arm studies evaluating the efficacy and safety of MSA in rGERD or comparative studies with proton pump inhibitor (PPI) or laparoscopic Nissen fundoplication (LNF) serving as the control published until April 2020. Primary outcome was the rate of postoperative PPI use, and secondary outcomes included postoperative GERD‐health‐related quality of life (GERD‐HRQL), normalization of acid exposure time (AET) and incidence of procedure‐related adverse events (AE).Results: Ten single‐arm studies, one randomized controlled trial and three cohort studies involving 1138 participants were included. Post‐MSA PPI withdrawal, significant GERD‐HRQL improvement and AET normalization were achieved in 87.0%, 88.0% and 75.0% of the patients, respectively. The incidence of postoperative dysphagia was 29% and endoscopic dilation was required in 7.4% of patients undergoing MSA. MSA showed a better efficacy in symptom control than PPI (PPI cessation: 91% vs 0%; GERD‐HRQL improvement: 81% vs 8%) and similar effectiveness but a lower risk of gas‐bloat syndrome (risk ratio [RR] 0.69, 95% confidence interval [CI] 0.51‐0.93, P = 0.01) and better reserved ability to belch (RR 1.48, 95% CI 0.76‐2.86, P = 0.25) compared with LNF.Conclusions: MSA was an effective and safe therapy for rGERD. Well‐designed randomized trials that compare the efficacy of MSA with other therapies are needed.